ERBB2 and neoplasm of esophagus: A tribody targeting human epidermal growth factor 2 where two HER2-specific scFvs were linked to CD16 [(HER2)2xCD16] was found to be superior to trazutumab against HER2-expressing breast, pancreatic, ovarian, and esophageal tumor cells with increased NK cell degranulation and release of granzyme B (207).